These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 22818082)

  • 1. The optimization of pyridazinone series of glucan synthase inhibitors.
    Kuang R; Wu H; Ting PC; Aslanian RG; Cao J; Kim DW; Lee JF; Schwerdt J; Zhou G; Herr RJ; Zych AJ; Yang J; Lam SQ; Jenkins DM; Sakwa SA; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5268-71. PubMed ID: 22818082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead optimization of a sulfonylurea-based piperazine pyridazinone series of glucan synthase inhibitors.
    Zych AJ; Lam SQ; Jenkins DM; Herr RJ; Ting PC; Lee JF; Kuang R; Wu H; Kim DW; Aslanian RG; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4896-9. PubMed ID: 22687744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors.
    Zhou G; Ting PC; Aslanian R; Cao J; Kim DW; Kuang R; Lee JF; Schwerdt J; Wu H; Herr RJ; Zych AJ; Yang J; Lam S; Wainhaus S; Black TA; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2011 May; 21(10):2890-3. PubMed ID: 21489787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.
    Heasley BH; Pacofsky GJ; Mamai A; Liu H; Nelson K; Coti G; Peel MR; Balkovec JM; Greenlee ML; Liberator P; Meng D; Parker DL; Wilkening RR; Apgar JM; Racine F; Hsu MJ; Giacobbe RA; Kahn JN
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6811-6. PubMed ID: 22672801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin.
    Apgar JM; Wilkening RR; Greenlee ML; Balkovec JM; Flattery AM; Abruzzo GK; Galgoci AM; Giacobbe RA; Gill CJ; Hsu MJ; Liberator P; Misura AS; Motyl M; Nielsen Kahn J; Powles M; Racine F; Dragovic J; Habulihaz B; Fan W; Kirwan R; Lee S; Liu H; Mamai A; Nelson K; Peel M
    Bioorg Med Chem Lett; 2015 Dec; 25(24):5813-8. PubMed ID: 26542966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors.
    Ting PC; Kuang R; Wu H; Aslanian RG; Cao J; Kim DW; Lee JF; Schwerdt J; Zhou G; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1819-22. PubMed ID: 21316223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a new class of glucosylceramide synthase inhibitors.
    Koltun E; Richards S; Chan V; Nachtigall J; Du H; Noson K; Galan A; Aay N; Hanel A; Harrison A; Zhang J; Won KA; Tam D; Qian F; Wang T; Finn P; Ogilvie K; Rosen J; Mohan R; Larson C; Lamb P; Nuss J; Kearney P
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6773-7. PubMed ID: 21974949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, anti-fungal and 1,3-β-D-glucan synthase inhibitory activities of caffeic and quinic acid derivatives.
    Ma CM; Abe T; Komiyama T; Wang W; Hattori M; Daneshtalab M
    Bioorg Med Chem; 2010 Oct; 18(19):7009-14. PubMed ID: 20813534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 1.
    Masubuchi K; Okada T; Kohchi M; Sakaitani M; Mizuguchi E; Shirai H; Aoki M; Watanabe T; Kondoh O; Yamazaki T; Satoh Y; Kobayashi K; Inoue T; Horii I; Shimma N
    Bioorg Med Chem Lett; 2001 Feb; 11(3):395-8. PubMed ID: 11212119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micafungin: a new echinocandin.
    Chandrasekar PH; Sobel JD
    Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK-5204: An orally active β-1,3-glucan synthesis inhibitor.
    Apgar JM; Wilkening RR; Parker DL; Meng D; Wildonger KJ; Sperbeck D; Greenlee ML; Balkovec JM; Flattery AM; Abruzzo GK; Galgoci AM; Giacobbe RA; Gill CJ; Hsu MJ; Liberator P; Misura AS; Motyl M; Kahn JN; Powles M; Racine F; Dragovic J; Fan W; Kirwan R; Lee S; Liu H; Mamai A; Nelson K; Peel M
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127357. PubMed ID: 32738971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of novel macrocyclic antifungal peptides.
    Mulder MP; Kruijtzer JA; Breukink EJ; Kemmink J; Pieters RJ; Liskamp RM
    Bioorg Med Chem; 2011 Nov; 19(21):6505-17. PubMed ID: 21940175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors.
    Walker SS; Xu Y; Triantafyllou I; Waldman MF; Mendrick C; Brown N; Mann P; Chau A; Patel R; Bauman N; Norris C; Antonacci B; Gurnani M; Cacciapuoti A; McNicholas PM; Wainhaus S; Herr RJ; Kuang R; Aslanian RG; Ting PC; Black TA
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5099-106. PubMed ID: 21844320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).
    Léger S; Black WC; Deschenes D; Dolman S; Falgueyret JP; Gagnon M; Guiral S; Huang Z; Guay J; Leblanc Y; Li CS; Massé F; Oballa R; Zhang L
    Bioorg Med Chem Lett; 2010 Jan; 20(2):499-502. PubMed ID: 20004097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel dendrimeric lipopeptides with antifungal activity.
    Janiszewska J; Sowińska M; Rajnisz A; Solecka J; Łącka I; Milewski S; Urbańczyk-Lipkowska Z
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1388-93. PubMed ID: 22230049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
    Yang SM; Tang Y; Rano T; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Lang W; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1437-41. PubMed ID: 24405703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure based design of novel irreversible FAAH inhibitors.
    Wang JL; Bowen SJ; Schweitzer BA; Madsen HM; McDonald J; Pelc MJ; Tenbrink RE; Beidler D; Thorarensen A
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5970-4. PubMed ID: 19765986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 2.
    Masubuchi K; Okada T; Kohchi M; Murata T; Tsukazaki M; Kondoh O; Yamazaki T; Satoh Y; Ono Y; Tsukaguchi T; Kobayashi K; Ono N; Inoue T; Horii I; Shimma N
    Bioorg Med Chem Lett; 2001 May; 11(10):1273-6. PubMed ID: 11392535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive assay for antifungal activity of glucan synthase inhibitors that uses germ tube formation in Candida albicans as an end point.
    Brayman TG; Wilks JW
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3305-10. PubMed ID: 14506045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential physiological functions of acceptor products of dextransucrase with cellobiose as an inhibitor of mutansucrase and fungal cell synthase.
    Kim M; Day DF; Kim D
    J Agric Food Chem; 2010 Nov; 58(21):11493-500. PubMed ID: 20929235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.